[HTML][HTML] Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer

Z Zuo, Z Zhou, Y Chang, Y Liu, Y Shen, Q Li, L Zhang - Genes & Diseases, 2024 - Elsevier
Abstract Ribonucleotide reductase M2 (RRM2) is a small subunit in ribonucleotide
reductases, which participate in nucleotide metabolism and catalyze the conversion of …

Promising predictive molecular biomarkers for cervical cancer

M Lizano, A Carrillo‑García… - International …, 2024 - spandidos-publications.com
Cervical cancer (CC) constitutes a serious public health problem. Vaccination and screening
programs have notably reduced the incidence of CC worldwide by> 80%; however, the …

Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART …

SA Gatz, AC Harttrampf, C Brard, F Bautista… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and
activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and …

[HTML][HTML] Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation

X Yang, X Hu, J Yin, W Li, Y Fu, B Yang, J Fan… - Nature …, 2024 - nature.com
Hyperthermic intraperitoneal chemotherapy's role in ovarian cancer remains controversial,
hindered by limited understanding of hyperthermia-induced tumor cellular changes. This …

[HTML][HTML] Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells

C Hieber, AHM Mustafa, S Neuroth, S Henninger… - Biomedicine & …, 2024 - Elsevier
Hyperactive FMS-like receptor tyrosine kinase-3 mutants with internal tandem duplications
(FLT3-ITD) are frequent driver mutations of aggressive acute myeloid leukemia (AML) …

Suit the Remedy to the Case: An Activatable DNA Damage Initiator for Postsurgical Therapy of Glioblastoma with TP53 Mutations

Y Hua, P Cao, W Wang, H Chen, Z Hu… - ACS Materials …, 2024 - ACS Publications
Glioblastoma (GBM) with TP53 mutations is a typical subtype of intracranial tumors that
rapidly recurs. Herein, we demonstrated that PD0166285 (PD), a dual-targeted inhibitor of …

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

X Zhu, Y Li, H Liu, Y Wang, R Sun, Z Jiang, C Hou… - Cell Chemical …, 2024 - cell.com
Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the biosynthesis of
nicotinamide adenine dinucleotide (NAD+), making it a potential target for cancer therapy …

The underlying mechanism of nuclear and mitochondrial DNA damages in triggering cancer incidences: Insights into proteomic and genomic sciences

S Saadi, NE Nacer, N Saari, AS Mohammed… - Journal of …, 2024 - Elsevier
The attempt of this review article is to determine the impact of nuclear and mitochondrial
damages on the propagation of cancer incidences. This review has advanced our …

[HTML][HTML] Clinicopathological and molecular genetic alterations in monomorphic–epitheliotropic intestinal T-cell lymphoma of the small intestine

B Zhou, M Guo, X Li, T Duan, L Peng, H Hao - European Journal of …, 2024 - Springer
Background Small intestinal monomorphic–epitheliotropic intestinal T-cell lymphoma
(MEITL) is a rare aggressive T-cell lymphoma originating in the gastrointestinal tract. This …

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL/MEITL, SPTCL, HSTCL)

E Marchi, JW Craig, M Kalac - Blood, 2024 - Elsevier
Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-associated T-
cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) …